Andreas D Haas1, Leigh F Johnson2, Anna Grimsrud3, Nathan Ford4, Catarina Mugglin1, Matthew P Fox5,6, Jonathan Euvrard2, Monique van Lettow7,8, Hans Prozesky9, Izukanji Sikazwe10, Cleophas Chimbetete11, Michael Hobbins12, Cordelia Kunzekwenyika13, Matthias Egger1,2. 1. Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. 2. Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa. 3. International AIDS Society, Cape Town, South Africa. 4. Department of HIV/AIDS World Health Organization, Geneva, Switzerland. 5. Department of Internal Medicine, Health Economics and Epidemiology Research Office, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 6. Global Health, Boston University School of Public Health, Boston, MA. 7. Dignitas International, Zomba, Malawi. 8. Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. 9. Division of Infectious Diseases, Department of Medicine, Tygerberg Academic Hospital, University of Stellenbosch, Cape Town, South Africa. 10. Centre for Infectious Diseases Research in Zambia, Lusaka, Zambia. 11. Newlands Clinic, Harare, Zimbabwe. 12. SolidarMed, Lucerne, Switzerland. 13. SolidarMed, Masvingo, Zimbabwe.
Abstract
BACKGROUND: The World Health Organization recommends differentiated antiretroviral therapy (ART) delivery with longer visit intervals for clinically stable patients. We examined time trends in visit frequency and associations between criteria for clinical stability and visit frequency in ART programs in Southern Africa. METHODS: We included adults on ART from 4 programs with viral-load monitoring, 2 programs with CD4 monitoring, and 4 programs with clinical monitoring of ART. We classified patients as clinically stable based on virological (viral load <1000 copies/mL), immunological (CD4 >200 cells/µL), or clinical (no current tuberculosis) criteria. We used Poisson regression and survival models to examine associations between criteria for clinical stability and the rate of clinic visits. RESULTS: We included 180,837 patients. There were trends toward fewer visits in more recent years and with longer ART duration. In all ART programs, clinically stable patients were seen less frequently than patients receiving failing ART, but the strength of the association varied. Adjusted incidence rate ratios comparing visit rates for stable patients with patients on failing ART were 0.82 (95% confidence interval: 0.73 to 0.90) for patients classified based on the virological criterion, 0.81 (0.69 to 0.93) for patients classified based on the clinical criterion, and 0.90 (0.85 to 0.96) for patients classified based on the immunological criterion for stability. CONCLUSION: Differences in visit rates between stable patients and patients failing ART were variable and modest overall. Larger differences were seen in programs using virological criteria for clinical stability than in programs using immunological criteria. Greater access to routine viral-load monitoring may increase scale-up of differentiated ART delivery.
BACKGROUND: The World Health Organization recommends differentiated antiretroviral therapy (ART) delivery with longer visit intervals for clinically stable patients. We examined time trends in visit frequency and associations between criteria for clinical stability and visit frequency in ART programs in Southern Africa. METHODS: We included adults on ART from 4 programs with viral-load monitoring, 2 programs with CD4 monitoring, and 4 programs with clinical monitoring of ART. We classified patients as clinically stable based on virological (viral load <1000 copies/mL), immunological (CD4 >200 cells/µL), or clinical (no current tuberculosis) criteria. We used Poisson regression and survival models to examine associations between criteria for clinical stability and the rate of clinic visits. RESULTS: We included 180,837 patients. There were trends toward fewer visits in more recent years and with longer ART duration. In all ART programs, clinically stable patients were seen less frequently than patients receiving failing ART, but the strength of the association varied. Adjusted incidence rate ratios comparing visit rates for stable patients with patients on failing ART were 0.82 (95% confidence interval: 0.73 to 0.90) for patients classified based on the virological criterion, 0.81 (0.69 to 0.93) for patients classified based on the clinical criterion, and 0.90 (0.85 to 0.96) for patients classified based on the immunological criterion for stability. CONCLUSION: Differences in visit rates between stable patients and patients failing ART were variable and modest overall. Larger differences were seen in programs using virological criteria for clinical stability than in programs using immunological criteria. Greater access to routine viral-load monitoring may increase scale-up of differentiated ART delivery.
Authors: Matthias Egger; Didier K Ekouevi; Carolyn Williams; Rita Elias Lyamuya; Henri Mukumbi; Paula Braitstein; Tyler Hartwell; Claire Graber; Benjamin H Chi; Andrew Boulle; François Dabis; Kara Wools-Kaloustian Journal: Int J Epidemiol Date: 2011-05-18 Impact factor: 7.196
Authors: Andreas D Haas; Olivia Keiser; Eric Balestre; Steve Brown; Emmanuel Bissagnene; Cleophas Chimbetete; François Dabis; Mary-Ann Davies; Christopher J Hoffmann; Patrick Oyaro; Rosalind Parkes-Ratanshi; Steven J Reynolds; Izukanji Sikazwe; Kara Wools-Kaloustian; D Marcel Zannou; Gilles Wandeler; Matthias Egger Journal: Lancet HIV Date: 2015-06-16 Impact factor: 12.767
Authors: Peter D Ehrenkranz; Jesus Mg Calleja; Wafaa El-Sadr; Ade O Fakoya; Nathan Ford; Anna Grimsrud; Kate L Harris; Suzanne L Jed; Daniel Low-Beer; Sadhna V Patel; Miriam Rabkin; William John Reidy; Annette Reinisch; George K Siberry; Leigh A Tally; Isaac Zulu; Irum Zaidi Journal: J Int AIDS Soc Date: 2018-03 Impact factor: 5.396
Authors: Trevor Peter; Clement Zeh; Zachary Katz; Ali Elbireer; Bereket Alemayehu; Lara Vojnov; Alex Costa; Naoko Doi; Ilesh Jani Journal: J Int AIDS Soc Date: 2017-11 Impact factor: 5.396
Authors: William B MacLeod; Jacob Bor; Sue Candy; Mhairi Maskew; Matthew P Fox; Katia Bulekova; Alana T Brennan; James Potter; Cornelius Nattey; Dorina Onoya; Koleka Mlisana; Wendy Stevens; Sergio Carmona Journal: BMJ Open Date: 2022-10-19 Impact factor: 3.006
Authors: Leigh F Johnson; Nanina Anderegg; Elizabeth Zaniewski; Jeffrey W Eaton; Peter F Rebeiro; Gabriela Carriquiry; Denis Nash; Marcel Yotebieng; Didier K Ekouevi; Charles B Holmes; Jun Y Choi; Awachana Jiamsakul; Giorgos Bakoyannis; Keri N Althoff; Annette H Sohn; Constantin Yiannoutsos; Matthias Egger Journal: AIDS Date: 2019-12-15 Impact factor: 4.177